> Oncopeptides presented interim data phase 2 on melflufen in late-stage relapsed-refractory multiple myeloma patients. One-third of patients had responded to the drug as of the cutoff. Release
> Nordic Nanovector shared updated phase 2 data in relapsed indolent non-Hodgkin's lymphoma. The updated data featured two more complete responses in patients taking Betalutin. Statement
> Autolus Therapeutics posted data on its next-generation CAR-T candidate AUTO3. The one-month manufacturing time and high rate of relapse cast a shadow over the overall response data. Release
> Freeline Therapeutics released early data on its pitch for the hemophilia B gene therapy market. The two patients who received a single infusion of the lowest dose achieved mean factor IX activity levels of 45%. Statement
> MaaT Pharma published results from a phase 1b/2a trial of its microbiome drug in patients with acute myeloid leukemia. The trial found the drug restored 90% of microbial species diversity within 40 days. Release
> Mereo Biopharma struck a deal to merge with OncoMed Pharmaceuticals. The merger will give Mereo a Nasdaq listing and an expanded pipeline. Statement